What is the main purpose of this 8-K filing?

This 8-K filing primarily serves to report Amgen's financial results for the three and nine months ended September 30, 2005, which were announced in a press release on October 19, 2005. It also highlights the company's use of non-GAAP financial measures to present a supplemental view of its performance.

What types of expenses is Amgen excluding from its non-GAAP financial measures?

Amgen is excluding a variety of items, including: write-offs of manufacturing assets, acquisition-related costs (like employee retention plans and amortization of acquired intangibles from Tularik and Immunex acquisitions), legal settlements, gains or losses from contract terminations (such as the Genentech manufacturing agreement), and expenses related to convertible notes. The specific items excluded vary between the three-month and nine-month periods and between 2005 and 2004.

Why does Amgen provide non-GAAP financial measures?

Amgen states that it provides these non-GAAP measures because it believes they offer useful supplementary information to investors. By excluding certain expenses and gains/losses (which may be one-time, non-cash, or otherwise not reflective of ongoing operations), the company aims to facilitate easier comparisons of its financial performance across different periods and against its own internal budgeting and planning.

Where can I find the actual financial numbers and the reconciliation between GAAP and non-GAAP results?

The actual financial results and the detailed reconciliations between GAAP and non-GAAP measures are provided in the press release dated October 19, 2005, which is attached as Exhibit 99.1 to this 8-K filing.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on October 25, 2005, reporting its financial results for the three and nine months ended September 30, 2005. The filing primarily details the company's use of non-GAAP financial measures to provide supplementary insights to investors, adjusting for significant one-time or non-cash items. These adjustments aim to offer a clearer view of operational performance by excluding factors like acquisition-related expenses, manufacturing asset write-offs, legal settlements, and gains/losses from contract terminations. Key adjustments for the nine months ended September 30, 2005, include a manufacturing charge, Tularik and Immunex acquisition-related costs (like employee compensation and amortization of intangibles), legal settlement amounts, a gain on termination of a Genentech manufacturing agreement, and expenses related to convertible notes. For the same period in 2004, adjustments covered Tularik and Immunex acquisition costs, a patent litigation settlement with Genentech, and amortization of acquired intangibles. Investors should carefully review the reconciliations provided in the referenced press release to understand the impact of these adjustments on reported earnings.

Key Highlights

1Amgen released its Q3 2005 financial results on October 19, 2005, via a press release, detailed in this 8-K filing.
2The company is providing non-GAAP financial measures to supplement GAAP results, offering clearer insights into operational performance.
3Key adjustments for 2005 include a significant manufacturing asset write-off, acquisition-related costs (Tularik, Immunex), legal settlements, Genentech agreement termination gain, and convertible note expenses.
4For the nine months ended September 30, 2005, Amgen excluded items such as a manufacturing charge, Tularik/Immunex acquisition costs, legal settlements, and the Genentech termination gain from its non-GAAP reporting.
5In 2004, non-GAAP adjustments focused on acquisition-related expenses (Tularik, Immunex), a patent litigation settlement with Genentech, and amortization of acquired intangible assets.
6The company believes these non-GAAP measures facilitate better period-over-period comparisons by excluding unusual or non-recurring items.
7Reconciliations between GAAP and non-GAAP measures are available in the full press release, attached as Exhibit 99.1.

AMGEN INC 8-K Report, Financial Results (Oct 25, 2005)

Summary

Key Highlights

Frequently Asked Questions